Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isao Yasumatsu

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Molecular Informatics|December 22, 2016
Quantitative Structure-activity Relationship (QSAR) Models for Docking Score CorrectionYoshifumi Fukunishi, Satoshi Yamasaki, Isao Yasumatsu, et al.
Journal of Chemical Information and Modeling|April 9, 2021
Flexibility and Cell Permeability of Cyclic Ras-Inhibitor Peptides Revealed by the Coupled Nosé-Hoover EquationKei Moritsugu, Koh Takeuchi, Narutoshi Kamiya, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2010
Discovery of imidazo[1,2-b]pyridazine derivatives as IKKbeta inhibitors. Part 1: Hit-to-lead study and structure-activity relationshipHiroki Shimizu, Shinji Tanaka, Tadashi Toki, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2011
Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 2: improvement of potency in vitro and in vivoHiroki Shimizu, Isao Yasumatsu, Tomoaki Hamada, et al.
Bioorganic & Medicinal Chemistry|May 18, 2017
Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activatorYumi Matsui, Isao Yasumatsu, Takashi Asahi, et al.
ACS Medicinal Chemistry Letters|July 17, 2024
Optimization of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors, Leading to the Potent DS08701581Toru Taniguchi, Isao Yasumatsu, Hiroaki Inagaki, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2020
Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidinesKatsushi Katayama, Ken Ishii, Eisuke Tsuda, et al.
Acta Crystallographica. Section F, Structural Biology Communications|March 3, 2018
A novel inhibitor stabilizes the inactive conformation of MAPK-interacting kinase 1Yumi Matsui, Isao Yasumatsu, Ken Ichi Yoshida, et al.
ACS Medicinal Chemistry Letters|January 25, 2021
Discovery of DS79932728: A Potent, Orally Available G9a/GLP Inhibitor for Treating β-Thalassemia and Sickle Cell DiseaseKatsushi Katayama, Ken Ishii, Hideki Terashima, et al.
Bioorganic & Medicinal Chemistry Letters|December 8, 2023
Synthesis, activity, and their relationships of 2,4-diaminonicotinamide derivatives as EGFR inhibitors targeting C797S mutationHideaki Kageji, Takayuki Momose, Yasuhito Nagamoto, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Molecular Informatics|December 22, 2016
Quantitative Structure-activity Relationship (QSAR) Models for Docking Score CorrectionYoshifumi Fukunishi, Satoshi Yamasaki, Isao Yasumatsu, et al.
Journal of Chemical Information and Modeling|April 9, 2021
Flexibility and Cell Permeability of Cyclic Ras-Inhibitor Peptides Revealed by the Coupled Nosé-Hoover EquationKei Moritsugu, Koh Takeuchi, Narutoshi Kamiya, et al.
Bioorganic & Medicinal Chemistry Letters|August 3, 2010
Discovery of imidazo[1,2-b]pyridazine derivatives as IKKbeta inhibitors. Part 1: Hit-to-lead study and structure-activity relationshipHiroki Shimizu, Shinji Tanaka, Tadashi Toki, et al.
Bioorganic & Medicinal Chemistry Letters|January 15, 2011
Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 2: improvement of potency in vitro and in vivoHiroki Shimizu, Isao Yasumatsu, Tomoaki Hamada, et al.
Bioorganic & Medicinal Chemistry|May 18, 2017
Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activatorYumi Matsui, Isao Yasumatsu, Takashi Asahi, et al.
ACS Medicinal Chemistry Letters|July 17, 2024
Optimization of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors, Leading to the Potent DS08701581Toru Taniguchi, Isao Yasumatsu, Hiroaki Inagaki, et al.
Bioorganic & Medicinal Chemistry Letters|August 12, 2020
Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidinesKatsushi Katayama, Ken Ishii, Eisuke Tsuda, et al.
Acta Crystallographica. Section F, Structural Biology Communications|March 3, 2018
A novel inhibitor stabilizes the inactive conformation of MAPK-interacting kinase 1Yumi Matsui, Isao Yasumatsu, Ken Ichi Yoshida, et al.
ACS Medicinal Chemistry Letters|January 25, 2021
Discovery of DS79932728: A Potent, Orally Available G9a/GLP Inhibitor for Treating β-Thalassemia and Sickle Cell DiseaseKatsushi Katayama, Ken Ishii, Hideki Terashima, et al.
Bioorganic & Medicinal Chemistry Letters|December 8, 2023
Synthesis, activity, and their relationships of 2,4-diaminonicotinamide derivatives as EGFR inhibitors targeting C797S mutationHideaki Kageji, Takayuki Momose, Yasuhito Nagamoto, et al.
Pageof 2